Jaguar Health Q1 2026 Call: No Relief, Royalty Cliff Looms

What happened

Jaguar Health's Q1 2026 earnings call detailed another quarter of stagnant revenue (~$3M) and persistent cash burn, with management reiterating efforts to restructure the crushing $27M annual royalty floor starting April 2026. No binding amendments or transformative partnerships were announced, leaving the company's $3.5M cash pile against $36M in current liabilities essentially unchanged. The call highlighted incremental orphan program data but failed to provide a credible path to solvency without massive dilution or a distressed recapitalization. With the April 2026 step-up now in effect, the fixed monthly obligation of $2.25M far exceeds current operating cash flow, making a going-concern risk imminent. The narrative remains one of survival financing rather than value creation, with equity holders facing near-total loss unless a miracle restructuring materializes.

Implication

The Q1 call reinforces that Jaguar Health remains a distressed option on crofelemer's orphan potential, but the financing cliff is immediate and severe. Without a binding royalty restructuring or major upfront partnership before mid-2026, equity will likely be wiped out. Only highly speculative investors willing to lose their entire stake should consider a position, and only if a credible restructuring is announced. Otherwise, capital is far better deployed elsewhere.

Thesis delta

The Q1 2026 call provided no evidence of progress on the key thesis breaker—restructuring the royalty obligations ahead of the April 2026 step-up. The STRONG SELL rating is reaffirmed with even higher conviction, as the bear case (55% probability of near-zero equity value) now appears more likely. Management's continued reliance on small ATM raises and equity-for-royalty swaps confirms the structural impairment of equity.